CYTH · Cyclo Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $217.0K | $97.2K | $190.6K | - | - | - | - | - | - | - |
| R&D | $5.49M | $3.49M | $2.85M | - | $3.47M | $3.17M | $3.40M | - | $2.86M | $1.87M |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $8.51M | $5.75M | $5.31M | - | $5.26M | $4.75M | $5.16M | - | $4.70M | $4.00M |
| D&A | - | - | $2.2K | - | - | - | $4.8K | - | - | - |
| Operating Income | ($8.29M) | ($5.64M) | ($5.12M) | - | ($4.77M) | ($4.63M) | ($5.01M) | - | ($4.25M) | ($3.46M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 | $0 |
| Net Income | ($8.83M) | ($5.98M) | ($4.34M) | - | ($4.77M) | ($4.64M) | ($5.01M) | - | ($4.25M) | ($3.45M) |
| EPS - Basic | ($0.31) | ($0.21) | ($0.15) | - | ($0.29) | ($0.33) | ($0.46) | - | ($0.50) | ($0.41) |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $928.0K | $1.12M | $3.00M | $9.25M | $1.80M | $841.5K | $915.2K | $1.54M | $4.29M | $7.45M |
| Accounts Receivable | $187.7K | $83.7K | $71.3K | $122.4K | $303.8K | $88.4K | $131.2K | $55.0K | $394.6K | $409.9K |
| Inventory | $236.1K | $241.0K | $242.5K | $254.4K | $209.8K | $236.6K | $244.5K | $254.5K | $271.1K | $260.6K |
| Accounts Payable | $5.02M | $3.86M | $3.67M | $4.86M | - | - | - | $2.23M | - | - |
| Current Assets | $3.26M | $4.45M | $6.57M | $12.32M | $5.51M | $4.55M | $3.99M | $4.16M | $8.42M | $11.78M |
| Total Assets | $5.25M | $4.72M | $7.16M | $13.25M | $5.60M | $4.64M | $4.10M | $4.22M | $8.49M | $11.84M |
| Current Liabilities | $18.72M | $9.83M | $6.54M | $8.47M | $6.62M | $6.10M | $4.50M | $3.48M | $2.88M | $2.10M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($13.47M) | ($5.12M) | $610.0K | $4.76M | ($1.05M) | ($1.48M) | ($438.9K) | $734.5K | $5.61M | $9.74M |
| Retained Earnings | ($103.01M) | ($94.18M) | ($88.20M) | ($83.86M) | ($78.21M) | ($73.44M) | ($68.81M) | ($63.80M) | ($58.82M) | ($54.57M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($6.18M) | - | - | - | ($4.37M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | $0 | - | - | - |
| Financing Cash Flow | - | - | ($69.3K) | - | - | - | $3.74M | - | - | - |
| CapEx | - | - | - | - | - | - | $0 | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($4.37M) | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 0.87 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -168.1% | -126.8% | -60.6% | - | -85.2% | -99.9% | -122.2% | - | -50.0% | -29.2% |
| Return on equity | 65.6% | 116.8% | -712.0% | - | 453.3% | 312.3% | 1140.9% | - | -75.7% | -35.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.17 | 0.45 | 1.01 | 1.45 | 0.83 | 0.75 | 0.89 | 1.19 | 2.93 | 5.60 |
| Quick ratio | 0.16 | 0.43 | 0.97 | 1.42 | 0.80 | 0.71 | 0.83 | 1.12 | 2.83 | 5.48 |
| Cash ratio | 0.05 | 0.11 | 0.46 | 1.09 | 0.27 | 0.14 | 0.20 | 0.44 | 1.49 | 3.55 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.39 | -0.92 | 11.74 | 2.78 | -5.32 | -3.13 | -9.34 | 5.74 | 1.51 | 1.22 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -73.9% | -21.6% | -2.3% | - | -12.2% | -34.1% | -70.6% | - | -10.1% | 4.0% |
| Net income growth (YoY) | -85.1% | -29.0% | 13.3% | - | -12.3% | -34.3% | -80.7% | - | -10.0% | 4.0% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | 9.5% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -1179.9% | -245.0% | - | 547.6% | - | - | - | -95.3% | -26.4% | -12.5% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Cyclo Therapeutics against the 5 most active filers in the same SIC group.